Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care
Authors: Michael L. Cheng, David B. Solit
Journal: Annals of Internal Medicine (2018)

Ideas and Opinions6 February 2018Opportunities and Challenges in Genomic Sequencing for Precision Cancer CareMichael L. Cheng, MD and David B. Solit, MDMichael L. Cheng, MDMemorial Sloan Kettering Cancer Center, New York, New York. (M.L.C.) and David B. Solit, MDMemorial Sloan Kettering Cancer Center, New York, New York (D.B.S.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-2940 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Cancer is a genomic disease defined by diverse somatic and germline alterations that promote aberrant cell growth. Tumor genomic profiling of single genes or limited gene panels to guide therapy selection is now part of standard management of several solid tumor types, including melanoma, lung cancer, colorectal cancer, and ovarian cancer. However, treatment of many solid tumors is still based on the site of origin rather than being personalized to the molecular alterations specific to an individual patient's cancer. Recent advances in next-generation sequencing (NGS) technology, coupled with decreasing costs, present a transformative opportunity to improve patient outcomes through implementation ...References1. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703-13. [PMID: 28481359] doi:10.1038/nm.4333 CrossrefMedlineGoogle Scholar2. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-20. [PMID: 26028255] doi:10.1056/NEJMoa1500596 CrossrefMedlineGoogle Scholar3. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726-36. [PMID: 26287849] doi:10.1056/NEJMoa1502309 CrossrefMedlineGoogle Scholar4. Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol. 2017;35 Suppl LBA2501. doi:10.1200/JCO.2017.35.18_suppl.LBA2501 CrossrefGoogle Scholar5. Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR, et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol. 2017;1:1-17. doi:10.1200/PO.17.00084 CrossrefGoogle Scholar6. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 2017;7:999-1005. [PMID: 28450426] doi:10.1158/2159-8290.CD-17-0146 CrossrefMedlineGoogle Scholar7. Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016;8:79. [PMID: 27460824] doi:10.1186/s13073-016-0333-9 CrossrefMedlineGoogle Scholar8. Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318:825-35. [PMID: 28873162] doi:10.1001/jama.2017.11137 CrossrefMedlineGoogle Scholar9. Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;1:1-16. doi:10.1200/PO.17.00011 CrossrefGoogle Scholar10. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016;34:155-63. [PMID: 26619011] doi:10.1038/nbt.3391 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Memorial Sloan Kettering Cancer Center, New York, New York. (M.L.C.)Memorial Sloan Kettering Cancer Center, New York, New York (D.B.S.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2940.Corresponding Author: David B. Solit, MD, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065; e-mail, [email protected]org.Current Author Addresses: Dr. Cheng: Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065.Dr. Solit: Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065.Author Contributions: Conception and design: M.L. Cheng, D.B. Solit.Drafting of the article: M.L. Cheng, D.B. Solit.Critical revision of the article for important intellectual content: D.B. Solit.Final approval of the article: M.L. Cheng, D.B. Solit.Administrative, technical, or logistic support: D.B. Solit.This article was published at Annals.org on 9 January 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCirculating tumor DNA in advanced solid tumors: Clinical relevance and future directionsCopyDetective: Detection threshold–aware copy number variant calling in whole-exome sequencing dataValue of Collaboration among Multi-Domain Experts in Analysis of High-Throughput Genomics DataFunctional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma 6 February 2018Volume 168, Issue 3Page: 221-222KeywordsCancer geneticsCancer treatmentCell free DNADrugsFood and Drug AdministrationForecastingGenomicsPathogensResearch designSequence analysis ePublished: 9 January 2018 Issue Published: 6 February 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...